title: [Minocycline quadruple versus tailored therapy in retreatment of Helicobacter pylori infection].
abstract: OBJECTIVE
  To compare eradication rates, safety and compliance of minocycline quadruple and tailored therapies in patients retreated for Helicobacter pylori (H.pylori) infection.
  
  
  METHODS
  Between January 2014 and June 2014, 135 patients with dyspepsia (18-70 years) and H. pylori infection after at least one previous eradication treatment at a tertiary hospital were randomly assigned to a 10-day treatment with minocycline quadruple therapy versus tailored triple regimen of PPI, amoxicillin and a third antibiotic. In the group of tailored therapy, medications were adjusted based on clarithromycin sensitivity and cytochrome P450 isoenzyme 2C19 genotype. Eradication status was assessed 4-12 weeks after treatment.
  
  
  RESULTS
  Although H. pylori eradication rates were higher in the minocycline therapy group than that in the tailored therapy group in intention-to-treat [84.1% (95%CI 75.0%-93.2%) vs 75.8%(95%CI 65.1%-86.5%), P=0.245] and per-protocol [88.3% (95%CI 80.3%-96.3%) vs 79.7%(95%CI 69.7%-89.7%), P=0.197] analyses, the differences between the two groups were not statistically significant.The incidence of adverse effects and compliance between the two groups were also comparable.
  
  
  CONCLUSIONS
  The tailored therapy in this study had a poor eradication efficacy in the retreated patients with H. pylori infection.Minocycline quadruple therapy achieved a relatively satisfactory eradication efficacy and may be an alternative choice for the retreatment of H. pylori infection.
  
  
  BACKGROUND
  Chinese Clinical Trial Registry, ChiCTR-TRC-13003975.
authors.affiliation: Department of Gastroenterology, Peking University Third Hospital, Beijing 100191, China.
authors.forename: Lingyun
authors.initials: L
authors.lastname: Zhang
authors.affiliation: Department of Gastroenterology, Peking University Third Hospital, Beijing 100191, China; Email: zhoumed@126.com.
authors.forename: Liya
authors.initials: L
authors.lastname: Zhou
authors.affiliation: Department of Gastroenterology, Peking University Third Hospital, Beijing 100191, China.
authors.forename: Zhiqiang
authors.initials: Z
authors.lastname: Song
authors.affiliation: Department of Gastroenterology, Peking University Third Hospital, Beijing 100191, China.
authors.forename: Yu
authors.initials: Y
authors.lastname: Ding
authors.affiliation: Department of Gastroenterology, Peking University Third Hospital, Beijing 100191, China.
authors.forename: Peng
authors.initials: P
authors.lastname: Bai
mesh_terms: D000658:Amoxicillin / Q000008:administration & dosage* / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000494:pharmacology; D044466:Asian People; D017291:Clarithromycin / Q000008:administration & dosage* / Q000494:pharmacology; D015169:Colony Count, Microbial; D065731:Cytochrome P-450 CYP2C19; D065692:Cytochrome P-450 CYP3A Inhibitors; D004359:Drug Therapy, Combination; D004415:Dyspepsia; D005260:Female; D005838:Genotype; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects / Q000302:isolation & purification*; D006801:Humans; D008826:Microbial Sensitivity Tests; D008911:Minocycline / Q000008:administration & dosage* / Q000494:pharmacology; D019233:Retreatment; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D065692:Cytochrome P-450 CYP3A Inhibitors; D000658:Amoxicillin; D065731:Cytochrome P-450 CYP2C19; D008911:Minocycline; D017291:Clarithromycin